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Abstract
Background: Assays detecting human antigen-specific antibodies are medically useful. However,
the usefulness of existing simple immunoassay formats is limited by technical considerations such
as sera antibodies to contaminants in insufficiently pure antigen, a problem likely exacerbated when
antigen panels are screened to obtain clinically useful data.
Results: We developed a novel and simple immunoprecipitation technology for identifying clinical
sera containing antigen-specific antibodies and for generating quantitative antibody response
profiles. This method is based on fusing protein antigens to an enzyme reporter, Renilla luciferase
(Ruc), and expressing these fusions in mammalian cells, where mammalian-specific post-
translational modifications can be added. After mixing crude extracts, sera and protein A/G beads
together and incubating, during which the Ruc-antigen fusion become immobilized on the A/G
beads, antigen-specific antibody is quantitated by washing the beads and adding coelenterazine
substrate and measuring light production.
We have characterized this technology with sera from patients having three different types of
cancers. We show that 20–85% of these sera contain significant titers of antibodies against at least
one of five frequently mutated and/or overexpressed tumor-associated proteins. Five of six colon
cancer sera tested gave responses that were statistically significantly greater than the average plus
three standard deviations of 10 control sera. The results of competition experiments,
preincubating positive sera with unmodified E. coli-produced antigens, varied dramatically.
Conclusion: This technology has several advantages over current quantitative immunoassays
including its relative simplicity, its avoidance of problems associated with E. coli-produced antigens
and its use of antigens that can carry mammalian or disease-specific post-translational
modifications. This assay should be generally useful for analyzing sera for antibodies recognizing any
protein or its post-translational modifications.
Background
Although it is clear that a normal host immune system rec-
ognizes and responds to tumors, we understand very little
about these complex tumor-host interactions. For
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example, it is not clear why tumor-associated proteins
elicit humoral responses, although it is often speculated
that such proteins can become antigenic when they are
overexpressed or represent an unusual or modified form
of a protein (e.g. altered spliced form), or are encoded by
mutant genes [1,2]. Efforts to identify antibody responses
to tumor antigens are motivated primarily by their diag-
nostic potential. Unfortunately, the immunoassay for-
mats available to most laboratories are less than ideal.
Most immunoassays use bacterial-expressed proteins for
detecting antigen-specific antibodies in human sera [2].
However, since such antigens do not carry post-transla-
tional modifications or may fold incorrectly, some immu-
noassays employ antigens produced in either yeast or
insect cells. While these antigens may fold correctly and
carry post-translational modifications, they will not carry
either mammalian- or disease-specific posttranslational
modifications. Tests employing bacterial-produced pro-
teins can produce high backgrounds because it is difficult
to completely eliminate or block serum antibodies reac-
tive with trace amounts of bacterial contaminants present
in most antigen preparations, even in pharmaceutical
grade preparations [3]. Therefore to overcome the biolog-
ical limitations and technical problems associated with
bacterially and non-mammalian-produced antigens, we
have developed a simple immunoassay that combines
conventional immunoprecipitation techniques with a
novel approach for the production of tumor antigens. The
tumor antigens are fused to an enzymatic reporter, Ruc,
and produced in mammalian cell cultures, where mam-
malian-specific post-translational modifications can be
added. This technology is based on our previously pub-
lished studies showing that a Ruc fusion with a human
protein retain the biological activities of both the reporter
and the human protein and can be used to detect weak
protein-protein interactions [4]. In the present applica-
tion, we utilized such fusions to detect protein-antibody
interactions.
Our immediate interest in this technology is that we
believe it can be used to systematically test the hypothesis
that, in sporadic cancers, mutant or overexpressed tumor-
associated proteins frequently induce humoral responses.
While variations of this hypothesis have be proposed, it
has not been vigorously tested for mainly historical and
technological reasons. Until recently, only a few fre-
quently mutated tumor-associated proteins were known
[5]. For example, in sporadic breast and colon cancers,
mutations in only a few proteins, p53 and SMAD4 or p53,
k-Ras and APC, respectively, had been identified prior to
2001. Recent molecular genetic studies have greatly
increased the number of genes known to be mutant in dif-
ferent types of sporadic cancers. For example, in colon
cancers over 15 different genes are known to be frequently
mutated [6-10], although individual patient tumors are
highly heterogeneous in their mutant gene spectrum. In
light of the fact that accurate classification of patient
tumors into well-defined subtypes by gene expression
profiling requires a panel of genes, each of which may be
specifically up- or down-regulated in only a small percent-
age of tumors [11-15], we hypothesize that monitoring
humoral immune responses to a panel of frequently
mutated and/or overexpressed tumor-associated proteins
in cancer patient sera can be used in an analogous man-
ner, but with the added advantage of not requiring tumor
tissue. In addition, existing data suggests that cancer
patients' antibody responses to these mutant proteins are
generally not limited to the mutated region of the protein.
For example, colon cancer patient sera containing anti-Ras
antibodies were equally reactive with either wild type or
mutant K-Ras recombinant proteins [16]. Epitope map-
ping experiments showed that these sera always reacted
with the C-terminus of K-Ras, although the mutated
amino acid is almost always at the N-terminus of Ras.
Similar results studying antibody responses to p53 were
obtained with sera from patients with breast, colorectal
and lung cancer [17]. While p53 mutations are in the cen-
tral region, the majority of immunodominant epitopes
are in the N- and/or C-termini of p53 [18,19]. For both
mutant CDX2 in colon cancer, and mutant B-Raf in
melanoma, patient antibodies react with both the wild
type protein and mutant epitopes [20,21]. Here we
describe a simple practical quantitative immunoprecipita-
tion assay that has a number of practical advantages
including that it is inexpensive, easy-to-perform and can
be used for detecting antigen-specific antibodies in clini-
cal sera samples. The proteins used here, as antigens are
frequently mutated or overexpressed in the types of
tumors carried by the patients whose sera are used to dem-
onstrate the usefulness of this new immunoassay format.
Results and discussion
Description of the immunoprecipitation assay
We used Ruc-tagged proteins to develop an immunopre-
cipitation assay that can quantitatively measure serum
antibody reactivity with protein antigens. Briefly, crude
extract containing the Ruc-antigen fusions, sera and pro-
tein A/G beads are mixed together and incubated, during
which the antigen fusions become immobilized; antigen-
specific antibody is then quantitated by washing the beads
and adding the colenterazine substrate. In these assays the
amount of light produced is proportional to the amount
of soluble fusion protein captured, directly or indirectly
by the antibody-bound beads. It should be noted that the
binding capacity of the protein A/G beads (Pierce Bio-
chemical) used to capture either purified monoclonal
antibodies or immunoglobulins from crude human or
animal antisera is quite high (24 µg of immunoglobulins/
µl of packed beads).BMC Biotechnology 2005, 5:22 http://www.biomedcentral.com/1472-6750/5/22
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The immunoprecipitation assay shows a linear range of 
detection with commercial antibodies
To illustrate this technology we generated Ruc fusion pro-
tein constructs for p53, K-Ras, c-Myc, β-catenin and
Smad4 by fusing cDNAs encoding these proteins (in
frame) to DNA encoding the C-terminus of Ruc in a mam-
malian expression vector, pREN2, which also encodes a
FLAG epitope tag at the N-terminus of Ruc. Transfections
into Cos1 cells of these different constructs yielded crude
extracts with 3–10 × 108 Ruc light units per 100 mm2
plate. We developed a standard assay format by using a
commercial anti-FLAG monoclonal antibody and Cos1
cell extracts containing Ruc-p53. When crude extract,
antisera and protein A/G beads were incubated together in
a single tube, the amount of immunoprecipitated Ruc-
p53 was directly proportional to the amount of anti-FLAG
antibody over a 1000-fold range of concentrations, with a
lower limit of detection of less than 5 picrograms (Figure
1). A commercial anti-p53 polyclonal antibody had a sim-
ilar capture capacity as reflected by a similar dose-
response curve, whereas a commercial polyclonal anti-
body against an unrelated antigen was unable to immu-
noprecipitate Ruc-p53 (Figure 1). Experiments using
commercial polyclonal antibodies for serine-15 phospho-
rylated p53 and acetylated p53 (lysine-373 and lysine-
382) also immunoprecipitated significant amounts of
Ruc-p53 (data not shown). Since the ability of these mod-
ification-specific antibodies to immunoprecipitated Ruc-
p53 was not competed by bacterially produced recom-
binant p53 protein (data not shown), this fusion protein
appears to contain at least two types of post-translational
modifications.
Human cancer patient sera contain antigen-specific 
antibodies
Since commercial antibodies can immunoprecipitate Ruc-
antigen fusions from crude Cos1 extracts, we tested
whether our simple assay format could also detect anti-
gen-specific antibodies in clinical sera samples. Our
motive for developing this technique was to have an
improved method for detecting cancer patient antibody
responses to tumor-associated proteins. Thus, we initially
tested it with a small number of clinical sera samples
taken from patients having three types of cancers, breast,
colon and head and neck. In order to maximize our
chances of detecting positive responses with these clinical
sera samples we chose to use p53 and four other tumor-
associated proteins (K-Ras, c-Myc, β-catenin and Smad4)
that are either frequently mutated and/or overexpressed in
various tumors. Wild type proteins were used as antigens
because several studies show that cancer patient sera
humoral immune responses are not restricted to or even
preferential for the epitopes that usually contain the
altered amino acids [16,18-21]. Cos1 extracts containing
Ruc-antigen fusions were used to test a total of 36 sera, 10
controls and 26 cancer patients (Table 1). Negative and
positive controls consisting of protein A/G beads alone
and 0.1 µg of anti-FLAG monoclonal antibody with pro-
tein A/G beads, respectively, were used for each experi-
ment. As expected, all sera had low reactivity with the
non-specific binding control protein, Ruc-alone (Table 1).
The positive control, anti-FLAG antibody, immunoprecip-
itated significant amounts of each of the Ruc-antigen
fusions. However, the fraction of the total Ruc activity that
could be captured varied amongst the different Ruc-anti-
gen fusions, possibly reflecting reduced accessibility to the
N-terminal FLAG epitope in some constructs (data not
shown). At least one cancer patient sera had statistically
significant antibody responses to each of the five Ruc
fusions, where significance is defined as a response greater
than the average plus three standard deviations of the 10
control sera (Table 1). Two of 10 head and neck, five of 10
breast, five of six colon cancer sera, but none of 10 healthy
control sera gave positive responses. Six of the 12 positive
tests were clustered in the six colon cancer patient sera and
two antigens, p53 and K-Ras (Table 1). The significance of
the relative response rates between different cancer-type
sera cannot be calculated because the sample sizes are
small and because no effort was made to match the con-
trol and patient sera by any criteria. Similarly, we cannot
conclude that either K-Ras and/or p53 may be more
Immunoprecipitation experiments with commercial  antibodies Figure 1
Immunoprecipitation experiments with commercial antibod-
ies. Various amounts of anti-FLAG monoclonal, anti-p53 pol-
yclonal or control (anti-WASP) polyclonal antibodies were 
mixed with 5 µl of a Cos1 extract containing Ruc-p53 for 1 h 
in the presence of protein A/G beads, processed and light 
units measured. The data shown is from one of three inde-
pendent experiments giving similar results.
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antigenic in colon cancers than either β-catenin or c-Myc.
Interestingly, the only multiple sample from any of the
patients, head and neck samples 11 and 12, are sequential
samples of which only the more recent sample showed
significant levels of anti-p53 antibodies. Since the pro-
teins used to test for antibodies in these 26 cancer patient
sera are often mutated and/or overexpressed in the three
types of cancer, our results are consistent with studies
indicating that these categories of proteins are often anti-
genic in cancer patients [2]. Our results with colon cancer
patient sera also support proposals that humoral immune
responses to panels of tumor-associated antigens may be
clinically useful when single antibody responses are not
informative [22,23]. In any case, the detection of cancer
sera from head and neck (20% sensitivity and 100% spe-
cificity), breast (40% sensitivity and 100% specificity),
and colon (86% sensitivity and 100% specificity)
obtained using a panel of five antigens are encouraging,
given that our assay is not yet optimized and the sample
sizes are small.
To determine whether patient antibody responses behave
in the same linear manner as the commercial antibodies,
we used the most reactive combination of patient sera and
fusion antigen in our small sample set, colon cancer sera
34 and the Ruc-p53 fusion. Although the amount of Ruc-
p53 captured by this serum is roughly linear with incuba-
tion time in the presence of protein A/G beads, reaching a
plateau by 30–60 minutes (Figure 2A), the relative
amount of immunoprecipitated Ruc-p53 was not com-
pletely linear with increasing amounts of sera (Figure 2B).
Since the two commercial antibodies used in Figure 1 are
highly purified, the non-linear dose-response curve of the
clinical sera sample could be due to interfering agents
such as anti-p53-specific IgA and IgM antibodies that rec-
ognize epitopes also recognized by IgG's but which bind
poorly to protein A/G beads [24]. We are exploring mod-
ifications of the assay format in order to produce a more
linear dose-response curve with clinical sera samples,
which if found, would facilitate assay standardization and
might increase sensitivity (note that 1–2 of the colon can-
cer responses to one of the antigens tested, β-catenin-∆1,
are barely below the cut-off value used to judge statistical
significance). If the presumed interfering agents also
affected ELISA tests, ELISA tests may significantly underes-
timate positive antibody responses and antibody titers
unless the sera are sufficiently diluted.
Competition experiments with unmodified proteins
While human humoral immune responses to post-trans-
lational modifications are often ignored and/or undetect-
able with existing technologies, recent studies
demonstrate that disease-related antibody responses can
occur to post-translational protein modifications [25]. In
at least one case, rheumatoid arthritis, antibody responses
to a post-translational modification, citrullination, is now
being intensely investigated as a potentially reliable dis-
ease indicator [26,27]. In light of these observations, we
asked whether each positive sera response seen in Table 1
could include antibodies that were directed toward post-
translational modifications by doing competition
experiments with unmodified E. coli-produced antigens.
These competition experiments (Table 2) show that 0–
100% of the immunoprecipitated Ruc-antigen fusions
were blocked by preincubating sera with 5 µg of the corre-
sponding  E. coli-produced antigens fused to maltose
binding protein (MBP). These differences occur even
between sera containing antibodies that recognize the
same antigen (e.g. p53 or K-Ras), proteins known to
contain post-translational modifications. These differ-
ences could mean that some tumors tend to produce
The immunoprecipitation assay with Ruc-p53 and a clinical  serum sample Figure 2
The immunoprecipitation assay with Ruc-p53 and a clinical 
serum sample. A: The immunoprecipitation activity is pro-
portional to incubation time. Tubes containing identical 
amounts of Ruc-p53 fusion protein extract (5 µl), patient 34 
sera (1 µl) and protein A/G beads were incubated for 5, 30, 
60, 90 and 120 min and processed for luciferase activity. B: 
Immunoprecipitation activity with various amounts of total 
crude patient 34 sera. Different amounts of patient sera 
(0.002 to 2 µl) were mixed with 5 µl of the Ruc-p53 fusion 
protein extract and incubated for 1 hour in the presence of 
protein A/G beads, processed and light units measured. The 
data shown is from one of three independent experiments 
giving similar results.
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proteins having more post-translational modifications or
that some cancer patient's immune system tend to pro-
duce significantly more antibodies that recognize post-
translational modifications. However, this data does not
exclude the possibility that some or all of each positive
antibody response detected is not even specific for the
antigen listed, since the apparent anti-p53 or anti-K-Ras
antibodies could be directed toward proteins that are in
complexes with these tumor antigens. If the tumor anti-
gens in these complexes were easily replaced by the MBP
fusions, one would see higher competition values than if
they were inefficiently replaced. Quantitative evaluation
of different competition results requires, at a minimum,
equal amount of reactive antibodies in each sera, a condi-
tion unlikely to be satisfied here, especially for the p53-
reactive sera. In addition, when we compared the dose-
Table 1: Immunoprecipitation capacity of 1 µl of human sera for Ruc-tumor antigen fusion proteinsa
Ruc p53 K-Ras Smad4 β-CAT-∆1c - M y c
Controls 1 194 19,319 480 10,582 269 4,752
2 9 9,830 1,064 3,575 835 2,913
3 8 5,236 445 1,773 211 2,006
4 3 8 3 , 1 8 74 7 71 , 9 1 95 3 01 , 8 3 1
5 14 11,908 795 6,884 161 3,346
6 3 1 5 , 3 9 08 2 31 , 7 2 42 3 52 , 0 5 0
7 76 22,526 1,909 6,996 259 11,816
8 29 15,338 943 8,043 445 3,475
9 10 12,282 1,162 19,380 215 3,623
10 9 11,130 1,109 4,429 501 5,060
 + 3 SDb 214 30,234 2,237 22,788 997 12,874
Head and Neck 11 0 10,904 508 2,721 196 2,193
12 0 31,593c 7 3 84 , 8 2 24 6 53 , 8 0 1
13 0 12,367 840 1,868 673 4,407
14 13 14,705 1,012 5,666 195 1,837
15 33 31,733c 1,189 5,264 552 4,107
16 121 4,828 621 980 279 1,974
17 0 8,517 1,160 8,396 336 2,958
18 0 19,240 1,283 9,485 327 1,814
19 0 11,224 1,517 4,454 410 4,370
20 28 7,322 554 2,261 723 2,343
Breast 21 44 13,211 960 10,219 308 5,988
22 10 18,814 696 42,970c 302 5,450
23 38 14,598 608 8,484 339 4,336
24 77 11,587 1,655 17,297 2363c 3,431
25 17 19,954 532 10,184 772 15,650c
26 25 9,538 195 5,962 300 1,646
27 10 7,815 2,561c 20,628 426 3,524
28 21 15,607 308 7,380 284 1,579
29 0 18,058 160 6,790 304 2,333
30 245c 25,479 1,919 9,727 495 3,787
Colon 31 4 6,656 1,204 3,252 267 1,763
32 40 20,928 4,293c 5,567 962 6,143
33 42 34,703c 1,472 10,830 716 4,906
34 51 300,943c 6,439c 2,610 992 3,789
35 35 5,670 3,306c 3,860 477 1,772
36 44 6,516 695 37,344c 371 2,395
aSera, FLAG-Ruc-fusion extracts, protein A/G beads and buffer were mixed together, incubated for 60 minutes and processed. The data, light units, 
is the average of two experiments and is corrected for background (beads plus extract, but no sera). The standard deviation for each value is also 
available (see Additional file 1).
bValues of the averages of the 10 control sera plus 3 standard deviations.
cNumbers in bold are statistically significant: greater than the average plus 3 standard deviations of the 10 control sera.
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response competition curves of sera 34 and the commer-
cial polyclonal anti-p53, adjusted to similar capacities for
immunoprecipitating Ruc-p53, we found a greater differ-
ence than indicated by the end-point values alone (Figure
3). Nevertheless, it is clear that our assay identifies patient
sera having qualitatively different humoral immune
responses to the same antigen. Additional tools, especially
antigens bearing only a single type of modification, will
be required to determine whether some or all of the pre-
sumed "low affinity" antibodies prefer epitopes bearing
post-translational modifications because many such anti-
bodies are likely to cross-react with unmodified epitopes.
We have preliminary observations suggesting that our
approach of making antigen-enzyme fusions and produc-
ing these fusions in mammalian cells may be superior to
conventional ELISA assays for detecting antigen-specific
antibody responses in human sera. Specifically, we have
tested the six colon cancer patient sera used here in a
standard sandwich type ELISA where the antigen were
fused to E. coli MBP and immobilized on ELISA plates
with a monoclonal anti-MBP antibody. In these ELISA
tests only two of the six colon cancer sera gave positive
responses with any of the five tumor-associated proteins
listed in Table 1 (data not shown). In any case, the
immunoprecipitation assay described here offers a practi-
cal approach for identifying post-translational modifica-
tion-specific antibody responses and studying their
medical relevance.
Conclusion
These results demonstrate that a simple quantitative
immunoprecipitation assay can identify human clinical
sera samples containing disease-related antigen-specific
antibodies. Quantitative results were obtained by using
easily prepared crude cell extracts containing post-transla-
tionally modified antigens fused to a light-producing
enzyme reporter. While the immunodetection of antigen-
enzymes is not new [28,29], by combining a robust
reporter, such as Ruc with the production of recombinant
Table 2: Competition of antibody responses by unmodified antigensa
Antigen/sera Control p53 K-Ras Smad4 β-CAT-∆1 c-Myc
p53/12 21% 32%
p53/15 20% 60%
p53/33 7% 88%
p53/34 11% 72%
K-Ras/27 5% 91%
K-Ras/32 25% 82%
K-Ras/34 4% 0%
K-Ras/35 16% 100%
Smad4/22 4% 92%
Smad4/36 0% 93%
β-catenin-∆1/24 23% 96%
c-Myc/25 0% 22%
aSera (1 µl), buffer and 5 µg competitor were incubated together for 60 min before adding the fusion extracts and protein A/G beads for an 
additional 60 minutes and processed. Background light units (beads plus extract but no sera) were subtracted before calculating percent 
competition. The first column identifies the antigen-sera combination tested. The other columns give the amount of competition obtained for each 
competitor antigen. All competitors, including the control (SPEC2), are MBP fusion proteins. Values are the averages plus from two independent 
experiments. The standard deviation for each value is also available (see Additional file 2).
Competition assays blocking Ruc-p53 immunoprecipitation  using bacterially-produced antigen Figure 3
Competition assays blocking Ruc-p53 immunoprecipitation 
using bacterially-produced antigen. Different amounts of E. 
coli-produced MBP-p53 were incubated with patient sera 34 
(0.5 µl) or commercial anti-p53 antibody (25 ng) for 1 h. Pro-
tein A/G beads and Ruc-p53 extract were then added and 
incubated for an additional 1 h, processed and light units 
measured. The data shown is from one of two independent 
experiments giving similar results.
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enzyme-antigen fusions in mammalian cells, we have cre-
ated a highly sensitive user friendly assay. This assay
requires fewer manipulations for reagent preparation and
less time than other immunoprecipitation methods
including avoiding having to purify and then radiolabel
the purified proteins or having to perform additional
analysis such as Western blotting after the
immunoprecipitations [30]. Producing the target antigens
in mammalian cells offers several potential advantages,
including having mammalian-specific and/or disease-spe-
cific post-translational modifications added to these anti-
gens. Thus, this immunoprecipitation assay provides a
simple, accessible, reliable and reproducible tool for
investigations aimed at documenting the role of post-
translational modification in disease. Although altered
post-translationally modified proteins occur in cancer
[31,32], future studies are needed to explore whether
there are detectable cancer patient-specific antibodies to
post-translationally-modified tumor proteins. The levels
and kinds of post-translational modifications on the Ruc-
antigen fusions can be manipulated by exploiting mutant
proteins, unique human cell lines (e.g. cell lines overex-
pressing tyrosine kinases) and various culture conditions.
Mammalian-produced antigens have additional advan-
tages over bacterial produced antigens including facilitat-
ing the study of antibody responses to very large proteins
(>100 kDa) that are difficult or impossible to produce as
intact proteins in E. coli. Our assay also avoids false posi-
tives caused by variable amounts of anti-E. coli antibodies
present in patient sera that react with the minor amounts
of E. coli proteins that co-purify with bacterial recom-
binant proteins; such contaminants are even present in
some pharmaceutical-grade recombinant protein prepara-
tions [3]. These advantages, along with the possibility of
improving the assay format, suggest that it may be worth-
while to use this assay to reevaluate the frequency with
which known tumor-associated proteins are detectably
antigenic in cancer patients. It is encouraging, although of
limited significance, that the frequencies of significant
antibody responses for two of the cancers are roughly
comparable to reports in the literature. Thus, in colon can-
cer patients we detected statistically significant antibody
responses to Ras and p53 in 50% and 33% of the sera,
respectively, compared to published reports of 33% for
Ras [16] and 26% for p53 [33]. In contrast, we did not
find any statistically significant antibody responses to p53
in breast cancer sera, which have been reported to occur
with 9% of patient sera [34]. Studies with much larger
sample numbers are clearly needed to make statistically
useful comparisons between our method and existing
methods.
This assay format and high throughput modifications
(e.g. magnetic A/G beads in a microtiter plate format) are
obviously directly applicable to detecting human sera
antibodies specific for any protein antigen of interest and
is likely to be useful for non-human sera, such as sera
obtained from animal models of disease, as well as for
antibodies in other bodily fluids including from ascites
and saliva. Variations of this immunoprecipitation assay
format might also be useful for studying other types of
protein-protein interactions.
Methods
Biochemical reagents and antibodies
Ultralink™ immobilized protein A/G beads were obtained
from Pierce Biotechnology Inc. Commercially available
antibodies were: mouse monoclonal anti-FLAG™ M2
from Sigma; rabbit anti-acetylated p53 from Upstate Bio-
chemicals and polyclonal rabbit anti-p53, polyclonal rab-
bit phosphoserine p53 and polyc lonal anti-WASP from
Santa Cruz Biotechnology.
Patient sera
The breast and colon cancer patient sera were obtained
from the University of Wisconsin collection, now kept at
Georgetown University Medical Center. Sera samples
from head and neck cancer patients and control sera were
collected by Dr. Radoslav Goldman at Georgetown Uni-
versity Medical Center (Washington, DC). The sex, age
and disease stages of these samples were not examined
until after the reactivities for all antigens were measured.
Generation of constructs encoding Ruc fused to tumor-
associated antigens
pREN2, a FLAG-epitope-tagged mammalian expression
vector, similar to the previously described pREN1 [4], was
used to generate all plasmids encoding Ruc fusions. The
tumor antigens are at the C-terminus and a single FLAG
tag is at the N-terminus of Ruc. A map of pREN2 is shown
in Figure 4. The cloned human cDNA fragments, ampli-
fied by PCR specific linker-primer adapters, were obtained
from Dr. E. Chang (p53), Dr. R. Lechleider (Smad4), Dr.
S. Byers (β-catenin), Dr. R. Dickson (c-Myc) and a publicly
available cDNA clone (IMAGE ID 6714574) for K-Ras.
Full-length coding sequences (excluding the initial
methionine) were used for the tumor antigens, with the
exception of the β-catenin, which encodes amino acids 2–
277. In every case a stop codon was included after the C-
terminal coding sequences of the tumor antigens. The
primer adapter sequences used for cloning each antigen
are as follows: p53, 5'-GAGGGATCCGAGGAGCCGCA
GTCAGAT-3' and 5'-GAGCTCGAGTCAGTCTGAGTCAG-
GCC-3'; K-Ras, 5'-GAGGGATCCACTGAATATAAACTT-
GTG-3' and 5'-GAGCTCGAGTTACATAATTACACACTT;
Smad4, 5'-GAGGGATCCGACAATATGTCTATTACG-3'
and 5'-GAGCTCGAGTCAGTCTAAAGGTTGTGG-3'; β-cat-
inin-∆, 5'-GAGGGATCCGCTACTCA AGCTGATTTG-3'
and 5'-GAGGTCGACTCAACCAGCTAAACGCACTGC-3';
and c-Myc, 5'-GAGG GATCCCTCAACGTTAGCTTCACC-BMC Biotechnology 2005, 5:22 http://www.biomedcentral.com/1472-6750/5/22
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3' and 5'-GAGCTCGAGTTACGCACAAGAGTTCCG-3'. For
Ruc alone, a separate construct was prepared containing a
stop codon at the end of the luciferase coding sequence in
place of the polylinker present in pREN2.
Immunoprecipitation assays with Ruc fusion proteins
Forty-eight hours after Fugene-6 transfection, Cos1 cells in
100 mm2 plates were washed twice with PBS, scraped with
1.0 ml of Buffer A (20 mM Tris, pH 7.5, 150 mM NaCl, 5
mM MgCl2, 1% Triton X-100) plus 50% glycerol and pro-
tease inhibitors (10 µg/mL each of leupeptin, aprotinin
and pepstatin), sonicated, centrifuged at 13,000 × g for 4
min, supernatants collected and used immediately or
stored at -20°C. Total luciferase activity in 1 µl of each
crude extract was measured by adding it to 100 µl of assay
buffer and substrate mixture (Renilla Luciferase Reagent
Kit, Promega) in a 12 × 75 mm glass tube, vortexing and
immediately measuring light-forming units with a
luminometer (GeneProbe) for 10 sec. Lysate prepared
from each 100 mm2 plate of transfected Cos1 cells typi-
cally provides enough extract for 60–200 assays. These
crude Cos1 extracts containing these Ruc fusions were sta-
ble for at least a few weeks when stored in 50% glycerol at
-20°C.
Structure of the pREN2 mammalian expression vector Figure 4
Structure of the pREN2 mammalian expression vector. Features indicated are CMV (cytomegalovirus) promoter, the N-termi-
nal FLAG epitope and Ruc. Sequences for Ruc are in bold. cDNAs for tumor antigens were cloned downstream of Ruc 
between the BamH1-Xho1 sites.
pRen-2
5.5 Kb
Ruc
BamH1
XhoI
CMV Promotor
atcagccgccacc ATG GAC TAC AAG GAC GAC GAT GAC AAG gga tct ACT TCG AAA……
M       D      Y      K       D D       D       D       K       G       S TS K
BamH1        EcoR1 HindIII XhoI XbaI Not
…… AAA  AAT  GAA  CAA GGA  TCC GAA TTC AAA AAG CTT CTC GAGAGT ACT TCT AGA GCG
KNEQ G      S       E      F      K       K     L       L     E S      T      S    R       A
KANr
FLAG Epitope
RENILLA luciferase
B
NdeI
1.5 kb
FLAG epitopeBMC Biotechnology 2005, 5:22 http://www.biomedcentral.com/1472-6750/5/22
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Immunoprecipitation assays were performed in 100 µl
volumes containng 6 µl of a 30% suspension of protein A/
G beads (in PBS), 1–10 µl sera (undiluted or diluted in
Buffer A plus 100 µg/ml BSA), sufficient Cos1 cell extract
to generate 1–5 million light units (usually 5 µl to 10 µl)
and Buffer A and incubated at 4°C with tumbling for 5–
120 minutes, washed 4–5 times with 1.2 ml of cold Buffer
A and once with 1.0 ml of PBS. After the final wash, the
beads, in a volume of about 10 µl, were added to the Ruc
substrate and light units measured as described above.
Since the capacity of these protein A/G is 24–32 mg/ml of
packed beads, 2 µl of packed beads should be sufficient to
immobilize most or all of the IgG in 1 µl of undiluted sera
(assumed to be 10 mg/ml IgG). The amount of IgG in 2 µl
of each sera that actually bound to protein A/G beads was
estimated by measuring the amount of bead-bound sera
released by a low pH glycine elution buffer and measured
using the BCA Protein Assay kit (Pierce Biotechnology
Inc.). The protein values varied from 2.0 µg to 7.3 µg/µl of
patient sera (see Additional file 3).
Competition experiments were performed using MBP
fusion proteins. Bacterial expression vectors were con-
structed by subcloning cDNA fragments into the pMAL-c2
vector (New England Biolabs). Recombinant MBP fusion
proteins were produced in bacteria, purified by amylose-
agarose affinity and eluted with maltose as described by
the manufacturer and stored frozen or in 50% glycerol at
-20°C. An MBP fusion containing the SPEC2 cDNA [35]
was produced and used as a non-specific inhibitor. The
integrity of the proteins was confirmed by SDS-PAGE elec-
trophoresis and protein concentration determined.
Diluted patient sera (10 µl used of sera diluted 1:10 in
buffer A containing 100 µg/ml BSA) were used in the com-
petition experiments described in Table 2, while only 5 µl
of 1:10 diluted colon patient sera 34 was used in the
experiments described in Figure 3.
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